首页> 外文会议>Enzyme Engineering Conference >ENGINEERING AND PRE-CLINICAL EVALUATION OF A HUMAN ENZYME IMMUNE CHECKPOINT INHIBITOR FOR CANCER THERAPY
【24h】

ENGINEERING AND PRE-CLINICAL EVALUATION OF A HUMAN ENZYME IMMUNE CHECKPOINT INHIBITOR FOR CANCER THERAPY

机译:癌症治疗人酶免疫检查点抑制剂的工程与临床评价

获取原文

摘要

The work presented here builds on the findings that the amino acid kynurenine (L-Kyn) synthesized via the enzymes indoleamine/tryptophan dioxygenase (IDO/TDO) mediates cancer immune suppression in a paracrine fashion and evaluates the hypothesis that systemic elimination of secreted Kyn in the extracellular space using an engineered human kynureninase enzyme (KYNase) to degrade it into inactive metabolites will have pronounced anti-tumor activity and overcome the limitations associated with IDO/TDO inhibitors.
机译:这里呈现的作品是通过酶吲哚胺/色氨酸二恶英酶(IDO / TDO)合成的氨基酸kynurenine(l-kyn)以帕拉卡曲碱时尚介导癌症免疫抑制,评估系统消除分泌kyn的假设使用工程化人犬果蛋白酶酶(kynase)将其降解到活性代谢物中的细胞外空间将具有明显的抗肿瘤活性并克服与IDO / TDO抑制剂相关的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号